

# THE LANCET

## Microbe

### **Supplementary appendix**

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Adler H, Ball R, Fisher M, et al. Low rate of bacterial co-infection in patients with COVID-19. *Lancet Microbe* 2020; **1**: e62.

**Table 1:**

	<b>Demographics</b>	
Total, n.	195	
Male, n (%)	118 (60.5%)	
Age in years, median (IQR)	69 (59–81)	
ICU admission, no.	24	
	<b>Outcomes</b>	
Remains inpatient, n (%)	16 (8.2%)	
Discharged, n (%)	117 (60.0%)	
Transferred out, n (%)	8 (4.1%)	
Died, n (%)	54 (27.7%)	
<b>Microbiology results</b>		
No. patients positive/patients tested (%)		
Blood cultures: Pathogens	2/128 (1.6%)	<i>Streptococcus pneumoniae</i>
Lower respiratory tract cultures:		
Pathogens	0/25	
Likely contaminants	5/25	<i>E coli</i> (n=2), <i>Pseudomonas</i> species (n=1), <i>Serratia</i> species (n=1), <i>Aspergillus</i> (n=1)*
Urinary pneumococcal antigen†	3/29	
Urinary <i>Legionella</i> antigen†	1/31	

Clinical characteristics and microbiology results of patients admitted with COVID-19. ICU, intensive care unit.

\* This patient had no clinical or radiological features of aspergillosis, and was discharged home after a week's hospitalisation without any antifungal treatment.

†BinaxNOW